PALI
NASDAQPalisade Bio Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$1.41-0.08 (-5.05%)
01:30 PM07:45 PM
News · 26 weeks44+600%
2026-04-192026-10-11
Mix1390d
- Other5(38%)
- Insider4(31%)
- Analyst2(15%)
- SEC Filings2(15%)
Latest news
25 items- ANALYSTRaymond James initiated coverage on Palisade Bio with a new price targetRaymond James initiated coverage of Palisade Bio with a rating of Outperform and set a new price target of $6.00
- INSIDERSEC Form 4 filed by Palisade Bio Inc.4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERSEC Form 4 filed by Palisade Bio Inc.4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERSEC Form 4 filed by Palisade Bio Inc.4 - PALISADE BIO, INC. (0001357459) (Issuer)
- PRPalisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA ClearanceCanadian clearance supports site activation and enrollment in the global study of once-daily oral PALI-2108 Primary efficacy results from approximately 204 patients with moderately to severely active ulcerative colitis expected in the second half of 2027 Denver, CO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that Health Canada has cleared the Company’s Clinical Trial Application (CTA) for ASCENTRA-UC, its global Phase 2 study evaluating PALI-2108 in patients with moderately to se
- PRPalisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBDASCENTRA-CD expected to enroll approximately 60 patients with moderate to severe Crohn’s disease First patient dosing targeted for Q1 2027; primary efficacy readout (Week 12 endoscopic response) targeted for Q1 2028 Phase 2 program builds on clinical experience in fibrostenotic Crohn’s disease demonstrating targeted tissue exposure, PDE4 target engagement and encouraging endoscopic activity Denver, CO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that the U.S. Food and Drug Admini
- PRPalisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation ForumPresentation scheduled for September 23, 2026 at 1:00 PM ET Access the webcast here Denver, CO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that JD Finley, Chief Executive Officer, and Mitchell Jones, M.D., Ph.D., President and Chief Medical Officer, will participate in the Stifel 2026 Virtual Immunology and Inflammation Forum. Date: September 23, 2026Time: 1:00 PM – 1:25 PM ETPresenters: JD Finley, Chief Executive Officer; Mitchell Jones, President & Chief Medical OfficerFormat:
- PRPalisade Bio to Participate in Upcoming Investor ConferencesDenver, CO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that members of management will participate in three healthcare investor conferences in September 2026. Wells Fargo 2026 Healthcare Conference Dates: September 8–10, 2026Location: Boston, MassachusettsFormat: Investor meetings Morgan Stanley 24th Annual Global Healthcare Conference Dates: September 14–16, 2026Location: New York, New YorkFireside Chat: Wednesday, September 16, 2026, from 10:00–10:35 AM ETFormat: In-person fi
- INSIDERCEO, CFO Finley John David gifted 88,400 shares and received a gift of 88,400 shares, decreasing direct ownership by 41% to 129,288 units (SEC Form 4)4 - PALISADE BIO, INC. (0001357459) (Issuer)
- PRPalisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 DevelopmentAdvancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD) Enrollment of first patient for Phase 2 ASCENTRA-UC trial of PALI-2108 expected in the second half of 2026; primary efficacy results expected in the second half of 2027 IND for Phase 2 ASCENTRA-CD trial of PALI-2108 for the treatment of Crohn’s disease expected in the second half of 2026 Strong balance sheet expected to support execution through key Phase 2 clinical readouts Denver, CO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade Bio" or the "Company"), a clinical-stage biopharm
- SECPalisade Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PALISADE BIO, INC. (0001357459) (Filer)
- SECSEC Form 10-Q filed by Palisade Bio Inc.10-Q - PALISADE BIO, INC. (0001357459) (Filer)
- ANALYSTOppenheimer initiated coverage on Palisade Bio with a new price targetOppenheimer initiated coverage of Palisade Bio with a rating of Outperform and set a new price target of $8.00
- INSIDERDirector Baltera Robert Jr. bought $88,698 worth of shares (45,000 units at $1.97), increasing direct ownership by 11% to 461,904 units (SEC Form 4)4 - PALISADE BIO, INC. (0001357459) (Issuer)
- PRPalisade Bio to Participate in the Leerink Partners Therapeutics ForumManagement to participate in investor meetings on July 14-15 in Boston Denver, CO, July 10, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation oral PDE4 inhibitor prodrugs for inflammatory bowel disease, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, will participate in the Leerink Partners Therapeutics Forum, taking place July 14-15, 2026, in Boston, Massachusetts. Management will participate in one-on-one meetings with institutional investors throughout the conference to discuss the Company's clinical developmen
- INSIDERDirector Baltera Robert Jr. bought $102,084 worth of shares (50,000 units at $2.04), increasing direct ownership by 14% to 416,904 units (SEC Form 4)4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERChief Medical Officer Jones Mitchell Lawrence converted options into 131,167 shares and sold $106,536 worth of shares (51,880 units at $2.05), increasing direct ownership by 539% to 94,009 units (SEC Form 4) to satisfy tax liability4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERCEO, CFO Finley John David exercised 335,300 shares at a strike of $0.00 and sold $303,343 worth of shares (146,798 units at $2.07), increasing direct ownership by 646% to 217,688 units (SEC Form 4) to cover withholding tax4 - PALISADE BIO, INC. (0001357459) (Issuer)
- SECSEC Form 144 filed by Palisade Bio Inc.144 - PALISADE BIO, INC. (0001357459) (Subject)
- INSIDERDirector Baltera Robert Jr. bought $59,400 worth of shares (30,000 units at $1.98), increasing direct ownership by 9% to 366,904 units (SEC Form 4)4 - PALISADE BIO, INC. (0001357459) (Issuer)
- PRPalisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative ColitisASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe First patient enrollment anticipated in the second half of 2026; primary efficacy results expected in the second half of 2027 IND clearance marks a major development milestone for PALI-2108 and supports continued advancement of the Company’s inflammatory bowel disease portfolio Denver, CO, June 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation oral PDE4 inhibitor prodrugs for inflammatory bowel disease, today announced that the U.S. Food and
- INSIDERDirector Baltera Robert Jr. was granted 336,904 shares (SEC Form 4)4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERSEC Form 3 filed by new insider Baltera Robert Jr.3 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERDirector Wei Binxian was granted 592,300 shares and converted options into 20,200 shares, increasing direct ownership by 71,637% to 613,355 units (SEC Form 4)4 - PALISADE BIO, INC. (0001357459) (Issuer)
- INSIDERDirector Williams Donald Allen converted options into 60,666 shares and was granted 1,498,900 shares, increasing direct ownership by 14,537% to 1,570,294 units (SEC Form 4)4 - PALISADE BIO, INC. (0001357459) (Issuer)
PALI FAQ
6 questionsWhat does Palisade Bio Inc. do?
Palisade Bio, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress, such as results from reduced blood flow to the intestine, infections, and surgery. The company was founded in 2005 and is based in Carlsbad...Where does PALI stock trade?
Palisade Bio Inc. (PALI) is listed on NASDAQ.What sector and industry is PALI in?
Palisade Bio Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about PALI?
Palisade Bio Inc. has had 8 recent analyst actions on file. The most recent action was from Raymond James: Outperform with a $600.00 price target on 2026-10-09. Recent price targets range from $500.00 to $2500.00.What companies are similar to PALI?
Notable peers in the same industry include GRPH (Graphite Bio Inc.), CABA (Cabaletta Bio Inc.), ACET (Adicet Bio Inc.), INMB (INmune Bio Inc.), TIL (Instil Bio Inc.). Compare PALI side-by-side with any of them on Quantisnow.How can I track PALI on Quantisnow?
Quantisnow aggregates Palisade Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PALI to receive live email and push alerts on every new disclosure.